Publications by authors named "Jose Javier Ferreiro"
Introduction: We evaluated the value of hematopoietic progenitor cells (HPCs) counted in Sysmex XN analyzers to predict the mobilization and collection of CD34+ cells in apheresis for stem cell transplantation.
Methods: Eighty patients who underwent stem cell transplantation were enrolled (50 autologous and 30 allogeneic). In the autologous group, patients were considered poor mobilizers when the CD34+ count was <10 × 10 /L or <20 × 10 /L in patients with multiple myeloma who were going to undergo two transplants.
Article Synopsis
- Patients with follicular lymphoma who don't respond well to their first treatment have a tough time surviving.
- A study showed that autologous stem cell transplantation (ASCT) can help these patients live longer, even if they didn't get a specific drug called rituximab before the transplant.
- In some cases, those who received ASCT after a short time from their first relapse had similar survival rates as those who didn't have early treatment failure, suggesting ASCT is a good option for many patients.
Secondary malignancies and survival outcomes after autologous stem cell transplantation for follicular lymphoma in the pre-rituximab and rituximab eras: a long-term follow-up analysis from the Spanish GELTAMO registry.
Bone Marrow Transplant
June 2018
Article Synopsis
- Overall survival (OS) is the most important measure for checking how well stem cell transplants work for people with follicular lymphoma (FL), but it can be hard to assess because the disease can take a long time to progress.
- Researchers looked at two earlier measures, progression-free survival at 24 months (PFS24) and complete response at 30 months (CR30) after transplant, to see if they could help predict overall survival.
- They found that if patients didn’t do well within 24 months or didn’t show a complete response by 30 months, they were likely to have worse overall survival, showing these measures could help guide treatments better.
High-dose chemotherapy supported by autologous stem cell transplantation (HDT/ASCT) has contributed to modify the natural history of follicular lymphoma (FL); however, an overall survival (OS) benefit has been demonstrated at relapse only after a rituximab-free chemotherapy regimen. A total of 655 patients with FL were reported to the Spanish GELTAMO (Grupo Español de Linfomas y Trasplantes de Médula Ósea) registry and underwent first ASCT between 1989 and 2007. A total of 203 patients underwent ASCT in first complete response (CR1), 174 in second complete response (CR2), 28 in third complete response (CR3), 140 in first partial response (PR1), 81 in subsequent PR, and 29 with resistant/refractory disease; 184 patients received rituximab before ASCT.
View Article and Find Full Text PDF